Sage Therapeutics - SAGE Stock Forecast, Price & News

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Wall Street Analyst Weigh In

SAGE has been the subject of a number of recent analyst reports. Stifel Nicolaus decreased their price target on shares of Sage Therapeutics from $58.00 to $56.00 in a research report on Tuesday, August 2nd. The Goldman Sachs Group decreased their price objective on shares of Sage Therapeutics from $85.00 to $73.00 and set a "buy" rating for the company in a report on Tuesday, May 24th. SVB Leerink decreased their price objective on shares of Sage Therapeutics from $50.00 to $40.00 and set a "market perform" rating for the company in a report on Monday, July 11th. Mizuho cut their price objective on shares of Sage Therapeutics from $41.00 to $37.00 in a research note on Wednesday, May 4th. Finally, StockNews.com upgraded shares of Sage Therapeutics from a "sell" rating to a "hold" rating in a research report on Wednesday, August 3rd. Nine research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, Sage Therapeutics presently has an average rating of "Hold" and an average price target of $54.47.

Sage Therapeutics Price Performance

SAGE Stock traded up $0.25 during midday trading on Wednesday, reaching $43.12. 519,669 shares of the stock were exchanged, compared to its average volume of 706,718. The stock has a market capitalization of $2.56 billion, a PE ratio of -5.06 and a beta of 1.43. Sage Therapeutics has a 52 week low of $27.36 and a 52 week high of $47.75. The company has a fifty day moving average price of $35.94 and a 200 day moving average price of $35.17.

Sage Therapeutics (NASDAQ:SAGE - Get Rating) last issued its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported ($2.13) earnings per share for the quarter, missing analysts' consensus estimates of ($2.12) by ($0.01). The firm had revenue of $1.50 million for the quarter, compared to the consensus estimate of $1.77 million. Sage Therapeutics had a negative return on equity of 30.10% and a negative net margin of 8,162.17%. The company's revenue was down 8.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.83) EPS. As a group, analysts anticipate that Sage Therapeutics will post -8.68 earnings per share for the current fiscal year.